Summary
Pharmada is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €169,021 and a net result of €83,597. Its solvency ranks better than 16% of 6,651 sector peers (NACE 64, financial year 2025). The company has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
17-06
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
31-12
Financial
Equity above €150,000equity €169,021 ▲96%
A profit in every financial year since 2024 builds equity to €169,021.
23-06
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
2023
19-12
Gazette deed
IncorporationAppointment: BROECHOVEN Kristel (director) · Founder · Founding capital9 facts ▸
Gazette deed
Incorporation
Appointment: BROECHOVEN Kristel (director) · Founder · Founding capital9 facts ▸
- Incorporation, “Pharmada” (deed in Dutch)
- Founder, BROECHOVEN Kristel
- Founding capital, €5,000
- Bank account, “bijzondere rekening, BE03 7340 7542 5084” (deed in Dutch)
- Other provision, “volstorting inbrengen” (deed in Dutch)
- Other provision, “beschikbare eigen vermogensrekening van de vennootschap” (deed in Dutch)
- Registered office clause, “1742 Sint-Katherina-Lombeek,Notestraat 56” (deed in Dutch)
- Director appointment, BROECHOVEN Kristel (director)
- Pre-incorporation commitments, “takeover, alle verbintenissen,alsook alle daaruit voortvloeiende verplichtingen,en alle handelingen gesteld door oprichter in naam en voor rekening van vennoots…” (deed in Dutch)
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
1 of 1 deed read